The board of Integrum appoints Scott Flora as acting CEO

Integrums CEO Rickard Brånemark has today agreed together with the board that he will leave the CEO role. The board announces that Scott Flora, board member since 2023, has been appointed acting CEO of Integrum AB. He takes office with immediate effect. The board will immediately start the recruiting process of a new CEO. Rickard Brånemark is appointed Chief Scientific Advisor.

Rickard Brånemark is the company's founder and board member. Rickard remains in the company in a new role as Chief Scientific Advisor. In his new role, he will provide support around the safe and effective use of Integrum's products and be the scientific and surgical specialist for customers and constituents involved in treating patients. Rickard will regularly hold a scientific meeting to review cases and results. 

"Being the founder of Integrum is an exciting journey. Our revolutionary implant system has been used successfully since 1990 and has given over 500 amputees new life. Everything has its time, and I will focus on my mission as a specialist and owner," comments Rickard Brånemark, Chief Scientific Advisor and founder.

"The board would like to thank Rickard Brånemark for his efforts to lead Integrum successfully from development company to establishment in the USA. We look forward to having Rickard remain in the company as Chief Scientific Advisor and a continued good collaboration on the board.  The groundwork has been done, the board assesses that Integrum needs new leadership for the next commercial steps", comments Bengt Sjöholm, chairman of the board of Integrum.

Scott Flora was born in 1955 and is an American citizen and has a bachelor's degree in marketing from Millikin University in the United States and has attended INSEADs global programs in France. Scott is a MedTech veteran who has held leadership positions at Smith & Nephew Ioptex (Ophthalmology), and Covidien Surgical Device, today Medtronic. Scott has previously, among other things, been CEO of Invuity today part of Stryker, OmniGuide, and Conventus Orthopaedics. He is today in addition to acting CEO and board member of Integrum, chairman of the board of Palliare Ltd, board member of  MAKO Surgical, now part of Stryker, board member of TubeWriter and Origami Surgical. Scott has previously advised Metalmark Capital and CVC Capital. Scott owns no shares in the company.

“The board warmly welcomes Scott Flora as acting CEO. Scott will lead Integrum into the next phase and is tasked with preparing the organization for future CEO. The board immediately starts the recruitment of a new CEO. Scott continues as a board member of Integrum AB and as chairman of the American subsidiary," comments Bengt Sjöholm, Chairman of the Board of Integrum. 

“I look forward to leading and supporting the Integrum Team as they continue to deliver Dr. Brånemark's groundbreaking innovations to amputees. Integrum’s innovations have the potential to improve amputee’s lives! To support this we will start the process of building a top tier organization to deliver best in class service to our constituents who participate in the care of amputee’s. This organization will deliver on its mission of improving amputee care and building sustainable value for our investors”, comments Scott Flora, CEO.

This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-09-2024 22:28 CET.

For more information, please contact:
Bengt Sjöholm, Chairman of the Board
Phone: +46 (0) 705 31 38 11
E-mail: bengt.sjoholm@bsjab.se

Certified Adviser
Carnegie Investment Bank AB (publ) is Certified Adviser.

About Integrum

Integrum is a publicly traded company (Nasdaq First North Growth Market: INTEG B) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA® Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA® Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.